NZ588209A - 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system - Google Patents
1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous systemInfo
- Publication number
- NZ588209A NZ588209A NZ588209A NZ58820909A NZ588209A NZ 588209 A NZ588209 A NZ 588209A NZ 588209 A NZ588209 A NZ 588209A NZ 58820909 A NZ58820909 A NZ 58820909A NZ 588209 A NZ588209 A NZ 588209A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorders
- benzodioxin
- dihydro
- methyl
- disease
- Prior art date
Links
- JHNURUNMNRSGRO-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanamine Chemical class C1=CC=C2OC(CN)COC2=C1 JHNURUNMNRSGRO-UHFFFAOYSA-N 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 230000010249 dopaminergic function Effects 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 208000028017 Psychotic disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000012661 Dyskinesia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000642 iatrogenic effect Effects 0.000 abstract 2
- XZLUXENLKSWQTA-LLVKDONJSA-N 2-methyl-n-[[(3r)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@H](CNCC(C)C)COC2=C1 XZLUXENLKSWQTA-LLVKDONJSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 206010008129 cerebral palsy Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- MAMVDUBLWPVXIQ-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCC)COC2=C1 MAMVDUBLWPVXIQ-UHFFFAOYSA-N 0.000 abstract 1
- DXONWYZCKWNSQB-LBPRGKRZSA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-propylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(CCC)CCC)COC2=C1Cl DXONWYZCKWNSQB-LBPRGKRZSA-N 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800598 | 2008-04-29 | ||
| PCT/EP2009/055137 WO2009133107A1 (en) | 2008-04-29 | 2009-04-28 | Modulators of dopamine neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ588209A true NZ588209A (en) | 2012-08-31 |
Family
ID=40940061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ588209A NZ588209A (en) | 2008-04-29 | 2009-04-28 | 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8524766B2 (enExample) |
| EP (1) | EP2271634B1 (enExample) |
| JP (1) | JP5514804B2 (enExample) |
| KR (1) | KR20100135325A (enExample) |
| CN (1) | CN102036976B (enExample) |
| AU (1) | AU2009242092A1 (enExample) |
| BR (1) | BRPI0911772A2 (enExample) |
| CA (1) | CA2722978A1 (enExample) |
| DK (1) | DK2271634T3 (enExample) |
| IL (1) | IL208289A0 (enExample) |
| MX (1) | MX2010011724A (enExample) |
| NZ (1) | NZ588209A (enExample) |
| RU (1) | RU2010141964A (enExample) |
| WO (1) | WO2009133107A1 (enExample) |
| ZA (1) | ZA201006932B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| CN102180856B (zh) * | 2011-03-01 | 2016-01-20 | 浙江华海药业股份有限公司 | 一种制备6-氟-3,4-二氢-2h-1-苯并吡喃-2-甲酸乙酯的方法 |
| JP5876140B2 (ja) | 2011-04-19 | 2016-03-02 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ |
| KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
| JP6481689B2 (ja) | 2014-06-26 | 2019-03-13 | 住友化学株式会社 | フェノール化合物の製造方法 |
| US9125866B1 (en) | 2015-01-28 | 2015-09-08 | King Saud University | Antidepressant compounds |
| CH712810B1 (de) * | 2015-07-21 | 2020-07-15 | Sumitomo Chemical Co | Verfahren zur Herstellung einer 4-(Trifluormethylsulfonyl)phenol-Verbindung. |
| WO2020239568A1 (en) | 2019-05-24 | 2020-12-03 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| WO2024182774A1 (en) * | 2023-03-01 | 2024-09-06 | Alexander Shulgin Research Institute, Inc. | Deuterated and fluorinated empathogens |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3058980A (en) * | 1962-10-16 | Substitution products of benzo- | ||
| US2906757A (en) * | 1959-09-29 | Their preparation | ||
| DE1110175B (de) * | 1957-01-08 | 1961-07-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von Benzodioxanderivaten |
| JPS55124781A (en) * | 1979-03-20 | 1980-09-26 | Shionogi & Co Ltd | 1,4-benzdioxanesulfonamide derivative |
| US5236055A (en) * | 1991-03-13 | 1993-08-17 | Canadian Aging & Rehabilitation Product Development Corporation | Wheel with coaxial drive system mounted in the wheelhub field of the invention |
| US5189171A (en) * | 1991-06-21 | 1993-02-23 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5166367A (en) * | 1991-06-21 | 1992-11-24 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5126366A (en) * | 1991-06-21 | 1992-06-30 | American Home Products Corporation | Aminophenoxyalkyl derivatives of benzodioxan |
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5235055A (en) | 1992-09-02 | 1993-08-10 | American Home Products Corporation | Antipsychotic quinoline derivatives of benzodioxanmethylamine |
| US5245051A (en) * | 1992-09-03 | 1993-09-14 | American Home Products Corporation | Antipsychotic chroman derivatives of benzodioxanmethylamine |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| US5663194A (en) * | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| US5684039A (en) * | 1995-07-25 | 1997-11-04 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| AR004229A1 (es) * | 1995-11-06 | 1998-11-04 | Wyeth Corp | Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| GB0007376D0 (en) | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| JP2005505586A (ja) * | 2001-10-04 | 2005-02-24 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 |
| TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| US20070208166A1 (en) * | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
| NZ550441A (en) * | 2004-05-05 | 2009-07-31 | Hoffmann La Roche | Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both |
| KR101245075B1 (ko) * | 2004-06-08 | 2013-03-18 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진 |
| MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| BRPI0610046A2 (pt) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | derivados de benzodioxano e benzodioxolano e usos destes |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| AR060493A1 (es) * | 2006-04-18 | 2008-06-18 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano. procesos de obtencion. |
| EP2026790A2 (en) * | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Co-therapy for the treatment of epilepsy and related disorders |
| TWI457122B (zh) * | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物 |
| EP2271635A1 (en) | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
-
2009
- 2009-04-28 DK DK09738151.1T patent/DK2271634T3/da active
- 2009-04-28 EP EP09738151.1A patent/EP2271634B1/en not_active Not-in-force
- 2009-04-28 CA CA2722978A patent/CA2722978A1/en not_active Abandoned
- 2009-04-28 BR BRPI0911772A patent/BRPI0911772A2/pt not_active IP Right Cessation
- 2009-04-28 NZ NZ588209A patent/NZ588209A/xx not_active IP Right Cessation
- 2009-04-28 KR KR1020107026636A patent/KR20100135325A/ko not_active Withdrawn
- 2009-04-28 AU AU2009242092A patent/AU2009242092A1/en not_active Abandoned
- 2009-04-28 RU RU2010141964/04A patent/RU2010141964A/ru not_active Application Discontinuation
- 2009-04-28 MX MX2010011724A patent/MX2010011724A/es unknown
- 2009-04-28 US US12/990,048 patent/US8524766B2/en not_active Expired - Fee Related
- 2009-04-28 WO PCT/EP2009/055137 patent/WO2009133107A1/en not_active Ceased
- 2009-04-28 CN CN200980115417XA patent/CN102036976B/zh not_active Expired - Fee Related
- 2009-04-28 JP JP2011506689A patent/JP5514804B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-21 IL IL208289A patent/IL208289A0/en unknown
- 2010-09-29 ZA ZA2010/06932A patent/ZA201006932B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8524766B2 (en) | 2013-09-03 |
| US20110105461A1 (en) | 2011-05-05 |
| MX2010011724A (es) | 2010-11-30 |
| AU2009242092A1 (en) | 2009-11-05 |
| ZA201006932B (en) | 2011-12-28 |
| CN102036976A (zh) | 2011-04-27 |
| EP2271634A1 (en) | 2011-01-12 |
| DK2271634T3 (da) | 2014-05-05 |
| JP2011518858A (ja) | 2011-06-30 |
| BRPI0911772A2 (pt) | 2017-06-27 |
| CN102036976B (zh) | 2013-05-01 |
| EP2271634B1 (en) | 2014-02-12 |
| JP5514804B2 (ja) | 2014-06-04 |
| WO2009133107A1 (en) | 2009-11-05 |
| IL208289A0 (en) | 2010-12-30 |
| KR20100135325A (ko) | 2010-12-24 |
| RU2010141964A (ru) | 2012-06-10 |
| CA2722978A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ588209A (en) | 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system | |
| BRPI0908738A8 (pt) | Composto, medicamento, uso de um composto, e, processo para preparar os compostos | |
| EA201170079A1 (ru) | Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида | |
| BR9707636A (pt) | Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo | |
| MX2011002705A (es) | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso. | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| NZ600008A (en) | Multicyclic compounds and methods of use thereof | |
| EA201170240A1 (ru) | Новые замещенные производные сульфамидов | |
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| MX2012010658A (es) | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| JP2011518858A5 (enExample) | ||
| NZ592571A (en) | Aryl piperazine and their use as alpha2c antagonists | |
| NZ630281A (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| RU2011120817A (ru) | Произволные 3-фенил-3-метоксипирролидина в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| MXPA02002695A (es) | Derivados de propilo tienoisoxazolil- y tienilpirrazolil-fenoxi sustituidos utiles como antagonistas de d4. | |
| UY29077A1 (es) | Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
| NZ592478A (en) | Process for synthesis of amino-methyl tetraline derivatives | |
| PT1216244E (pt) | Derivados de benzisoxazolil- piridoisoxazolil- e benztienil-fenoxi uteis como antagonistas d4 | |
| BR112015000313A2 (pt) | piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona | |
| JP2012509860A5 (enExample) | ||
| BR0316482A (pt) | Processo aperfeiçoado para a preparação de indenos 1,3 substituìdos | |
| EP1469730A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| MX365283B (es) | Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical. | |
| PH12013501724A1 (en) | Glycine transporter-inhibiting substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 APR 2016 BY HENRY HUGHES Effective date: 20130429 |
|
| LAPS | Patent lapsed |